Skip to main content

Table 3 Percent of patients with RTOG grades 0-2 gastrointestinal (GI) and genitourinary (GU) toxicity

From: Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes

Toxicity Grade n Months post treatment
During SBRT 1 4 7-12 13-18
50 50 46 41 36
GI 0   84% 88% 100% 100% 100%
1   16% 8% (6%)a 0 0 0
2   0 4% (4%)a 0 0 0
GU 0   38% 44% 63% 71% 75%
1   32% 26% (4%)a 20% 17% 14%
2   30% 30% (12%)a 17% 12% 11%
  1. aPercent in parentheses at one-month post treatment represents patients that were asymptomatic during SBRT but developed toxicity during the 4 weeks after completing radiotherapy